We’re working to meet the needs of acute care practitioners and their patients

Our in-depth knowledge of the postsurgical pain market, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

Pacira Core Values

We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.

Patient safety and welfare are our top priority at all times.

Our people are our greatest asset.

We are passionate about what we do.

Our thoughts are shared generously.

Building trust is essential.

Teamwork is the cornerstone of our business success.

Dedicated Leadership

Our management team has unparalleled experience in the hospital marketplace and a track record of successfully launching acute care products. This experience helps us to ensure that Pacira products, pipeline programs, and partnerships in the marketplace are consistently of the highest quality. As a public company (NASDAQ: PCRX), we hold our shareholders in the same high regard as we do the physicians and patients we serve.

david-stack

David Stack

Chief Executive Officer and Chairman

Dave Stack is currently the Chief Executive Officer and Chairman of Pacira Pharmaceuticals, Inc. He is also a Managing Director at MPM Capital.

From September 2001 until August 2004, Mr. Stack was President, CEO and Director of The Medicines Company (NASDAQ: MDCO). Prior to The Medicines Company, he was the CEO of Stack Pharmaceuticals, Inc., where The Medicines Company was one of its primary customers. From May 1995 to December 1999, he served as the President and General Manager of Innovex, Inc., responsible for the Americas. Innovex, Inc. was a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers, and was sold to Quintiles in November 1997 for $897 million. From April 1993 to May 1995, he was the Vice President of Business Development and Marketing for Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company focusing on monoclonal antibodies in infectious disease and oncology. From May 1992 to March 1993, Mr. Stack was the Director of Business Development and Planning for Infectious Disease, Oncology and Virology for Roche Labs where he was the Therapeutic World Leader for Infectious Disease. Prior to that role, he held various positions with Roche Labs for approximately 12 years and was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a Bachelor of Science in Biology from Siena College, where he is currently a Trustee.

Mr. Stack was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Amarin Corporation plc and Medivo Inc, serves as Chairman of Chiasma, Inc. and is on the Board of Directors of the Biotechnology Industry Organization’s (BIO) Emerging Company and Health Sections.

Kristen Williams

Kristen Williams, JD

Chief Administrative Officer and Secretary

Kristen Williams worked with the company as a legal consultant before joining as Corporate Counsel in December 2011. Since then, she has been promoted to Vice President, General Counsel in 2013 and to Chief Administrative Officer, General Counsel and Secretary in 2014. Prior to joining Pacira, she was Vice President, Corporate Compliance and Assistant General Counsel for Bioenvision, Inc. Prior to this role, she practiced corporate law at Paul Hastings LLP in New York, where her practice encompassed all aspects of public and private mergers and acquisitions, corporate finance, and securities law and compliance, with a core focus in the healthcare industry.

Ms. Williams earned a Bachelor of Science Degree in Business Administration from Bucknell University and a JD Degree from the University of Denver, College of Law in Denver, CO.

Charles A. Reinhart III

Charles A. Reinhart III

Chief Financial Officer

In 2016, Charles A. Reinhart III joined Pacira as Chief Financial Officer, responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis, and investor relations.

Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc., Archimedes Pharma Ltd. and PharmAthene, Inc. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. Mr. Reinhart has successfully built and managed finance organizations within rapidly growing companies, responsible for accounting and financial reporting, financial planning and analysis, tax, treasury, risk management and procurement. He has worked closely with commercial teams to evaluate sales operations, monitor product pricing and implement contracting strategies. In addition, he has significant experience in investor relations, corporate development and capital raising. He has been integrally involved in equity and debt financing transactions, as well as the evaluation, acquisition and integration of multiple products and companies.

Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.

Scott Braunstein

Scott Braunstein, MD

Chief Operating Officer

Scott Braunstein joined Pacira in 2015, bringing over 20 years of knowledge and experience from his time both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles advising on strategy and organizational objectives for biotechnology and pharmaceutical companies. As Chief Operating Officer, he oversees the company’s commercial and medical affairs functions while also managing strategy and corporate development activities.

Dr. Braunstein earned his medical degree from the Albert Einstein College of Medicine, completed his internal medical residency at Cornell University-New York Hospital and conducted additional research in immunology and wound healing from 1993 to 1994 at Rockefeller University. He also provided academic instruction as Assistant Clinical Professor for Columbia University and the Albert Einstein College of Medicine.

Richard Scranton

Richard Scranton, MD, MPH

Chief Scientific Officer

As Chief Scientific Officer, Richard Scranton directs the company’s clinical research, scientific communications, market access strategies, and health outcomes research and analytics for EXPAREL.

Dr. Scranton joined Pacira in 2011. He has a Master’s Degree in Public Health, Clinical Epidemiology/Clinical Effectiveness from the Harvard School of Public Health and earned his MD from the Quillen College of Medicine at East Tennessee State University. He completed his residency in the U.S. Navy and was honorably discharged as lieutenant commander, continuing as an Assistant Professor at Harvard Medical School.